Thomvest
That's very good conditions for a loan for a small biotech.
Look at Thomvest past investment, you will find out they know what they are doing!
I like the idea to push a little farther the therapeutic R&D. I night repeat my self, but Intermune have a market cap of $ 1.4B with only Esbriet (Pirfenidone) in the portfolio. PBI-4050 have at least the same potential, if not more.
Stars are starting to get in line!